| Literature DB >> 26019390 |
A P Casani1, N Cerchiai1, I Dallan1, V Seccia1, S Sellari Franceschini1.
Abstract
Many types of approaches allow extra-capsular dissection in the deep parotid parenchyma in the treatment of benign tumours. A transcervical approach (TCA), transparotid approach (TPA) and a combined transcervical-transparotid approach (TPTCA) are the three main procedures performed to expose the deep parenchyma. We conducted a retrospective chart review enrolling 24 consecutive patients treated for benign tumours affecting the deep lobe of the parotid. Review of the surgical data was accompanied by careful follow-up to establish surgical morbidity, functional (Frey's Syndrome and first-bite syndrome) and aesthetical outcomes. A TPA was performed in the majority of cases; in 26% superficial parotidectomy was not required (selective deep parotidectomy). Minor's test showed a low rate of Frey's syndrome (3 cases of 23, 13%). No long-lasting first-bite syndrome was reported. Some additional procedures were easily performed in order to improve aesthetical results (rotational flap of sternocleidomastoid muscle, free abdominal fat transfer); these had the same results as selective deep parotidectomy. TCA (or TPTCA) ensures the best control of the facial nerve, providing good exposure and good functional and aesthetical results (without sparing the superficial parenchyma if additional techniques are performed with the aim of reducing skin depression in the treated area). The choice of the approach should have only the aim of safe resection and should not be influenced by aesthetical outcome; the craniocaudal level of the tumour seems to be the best indicator of the feasibility of the procedure also considering the branches of the facial nerve. In our experience, mandibulotomy can always be avoided.Entities:
Keywords: Deep lobe; Frey's syndrome; Parapharyngeal space; Parotid; Salivary gland tumours
Mesh:
Year: 2015 PMID: 26019390 PMCID: PMC4443562
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.124
Fig. 1.(A) tumour of the deep lobe (asterisk) under the superficial parenchyma, removed performing an ECD after TPA (a portion arising from the deep tumour occupies part of the superficial lobe and is surrounded by some branches of the facial nerve); (B) the tumour (pleomorphic adenoma) after the procedure.
Fig. 2.Large tumour of the deep lobe widely occupying the parapharyngeal space (black asterisk) and displacing the tonsil lodge (black arrow).
Fig. 3.Four consecutive coronal preoperative MRI scans in a TCA; the images show the presence of healthy salivary tissue (black asterisk) between the tumour (white arrow) and the LPM (white asterisk).
Fig. 4.Pleomorphic adenoma (black asterisk), occupying both the superficial and the deep lobe treated via a TPTCA.
Clinical features and results of the surgical approach in the 24 patients.
| ID | SEX | Age | Year | Localisation of the tumour | Approach | Superficial lobe removed | Additional procedure | Pathology | Clinical and radiological follow-up | FBS | Positive minor's test | Luna- Ortiz scoring | Aesthetic outcome (1-5) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 65 | 2011 | DL | TPA | Yes | Abdominal fat transfe | Basal Cell Adenoma | NED | No | No | 0 | 5 |
| 2 | F | 50 | 2010 | DL | TPA | Yes | Abdominal fat transfe | Pleomorphic Adenoma, Lipoma | NED | No | Yes | 1 | 4 |
| 3 | F | 30 | 2011 | DL | TPA | No (selective deep parotidectomy) | No | Pleomorphic Adenoma | NED | No | No | 0 | 5 |
| 4 | M | 61 | 2011 | DL | TPA | No (selective deep parotidectomy) | No | Salivary Duct Cyst | NED | No | No | 0 | 4 |
| 5 | M | 62 | 2009 | DL | TPA | Yes | SCM flap | Warthin's Tumour | NED | No | No | 0 | 5 |
| 6 | F | 67 | 2011 | DL | TPA | Yes | Abdominal fat transfer | Pleomorphic Adenoma | NED | No | No | 0 | 5 |
| 7 | M | 45 | 2011 | SLDL | TPA | Yes | No | Multifocal Warthin's Tumour | Recurrence | No | No | 0 | 3 |
| 8 | F | 58 | 2011 | DL | TPTCA | Yes | Abdominal fat transfer | Pleomorphic Adenoma | NED | No | No | 0 | 5 |
| 9 | M | 49 | 2009 | DL | TPTCA | Yes | No | Pleomorphic Adenoma | NED | No | Yes | 6 | 4 |
| 10 | F | 45 | 2010 | DL | TPTCA | Yes | SCM flap | Pleomorphic Adenoma | NED | Yes | Yes | 5 | 5 |
| 11 | F | 47 | 2010 | DL | TPA | Yes | Abdominal fat transfer | Pleomorphic Adenoma | NED | No | No | 0 | 5 |
| 12 | F | 56 | 2011 | DL | TPA | Yes | No | Pleomorphic Adenoma | NED | No | No | 0 | 3 |
| 13 | F | 61 | 2010 | DL | TPA | No (selective deep parotidectomy) | No | Pleomorphic Adenoma | NED | No | No | 0 | 4 |
| 14 | F | 42 | 2011 | SLDL | TPA | Yes | No | Pleomorphic Adenoma | NED | No | No | 0 | 1 |
| 15 | M | 33 | 2009 | DL | TPA | No (selective deep parotidectomy) | No | Pleomorphic Adenoma | NED | No | No | 0 | 5 |
| 16 | F | 78 | 2010 | DL | TPA | Yes | SCM flap | Pleomorphic Adenoma | NED | No | No | 0 | 4 |
| 17 | M | 46 | 2011 | DL | TPA | Yes | Abdominal fat transfer | Warthin's Tumour | NED | No | No | 0 | 5 |
| 18 | F | 40 | 2011 | DL | TPA | No (selective deep parotidectomy) | No | Cystadenoma | NED | No | No | 0 | 5 |
| 19 | M | 58 | 2010 | DL | TPA | Yes | No | Schwannoma | NED | No | No | 0 | 3 |
| 20 | M | 52 | 2010 | SLDL | TPA | Yes | No | Multifocal Warthin's Tumour | NED | No | No | 0 | 4 |
| 21 | M | 66 | 2011 | SLDL | TPA | No (revision) | No | Pleomorphic Adenoma | NED | No | No | 0 | 4 |
| 22 | M | 38 | 2010 | DL | TPA | No (revision) | No | Salivary Duct Cyst | Recurrence | No | No | 0 | 2 |
| 23 | F | 51 | 2011 | SLDL | TPTCA | No (revision) | No | Oncocytoma | NED | Yes | No | 0 | 2 |
| 24 | M | 65 | 2011 | DL | TCA | No (TCA) | No | Pleomorphic Adenoma | NED | Yes | No | 0 | 5 |
DL: Deep Lobe; SL: Superficial Lobe; TPA: Trans Parotid Approach; TPTCA: combined Trans Parotid and Trans Cervical Approach; TCA: Trans Cervical Approach; SCM: Sternocleidomastoid muscle; NED: No Evidence of Disease.